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Background: Osteoarthritis (OA) is a common chronic disease of the joints. Genetic factors may play a role in its
development, and polymorphisms in the estrogen receptor alpha gene (ERα) have been associated with OA.
However, previous studies into this relationship have reported inconsistent results, so we aimed to systematically
review the association between ERα polymorphisms and OA susceptibility.
Methods: We conducted a comprehensive literature search of Ovid MEDLINE, EMBASE, CBM, and PubMed
databases, and Google scholar, and identified 11 eligible studies that examined the association between ERα
polymorphisms and OA susceptibility. We carried out a meta-analysis of these studies based on ERα XbaI
(rs9340799) and PvuII (rs2234693) genotypes.
Results: Seventeen comparisons involving 10 European and seven Asian populations of 5,325 OA patients and 10,834
controls were included in the study. The ERα XbaI polymorphism were significantly associated with OA in Europeans (AA
vs. AG + GG: OR = 1.17, 95% confidence interval (CI) = 1.02–1.34, P = 0.03; AG vs. AA + GG: OR = 0.86, 95% CI = 0.75–0.99,
P = 0.04) but not in Asian populations. No association was found between OA and the ERα PvuII polymorphism in any
population (C vs. T, OR = 0.98, 95% CI = 0.93–1.03, P = 0.37; CC vs. TT + CT, OR = 0.97, 95% CI = 0.89–1.06, P = 0.55; CT vs.
CC + TT, OR = 0.99, 95% CI = 0.92–1.06, P = 0.75; TT vs. CC + CT, OR = 1.01, 95% CI =0.92–1.12, P = 0.79).
Conclusions: This study suggested that there may be a weak relationship between the ERα XbaI polymorphism and OA
in Europeans but not Asians, and that the ERα PvuII polymorphism was not associated with OA in either population.
However, large well-designed studies are necessary to confirm these results in more homogeneous populations.
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Osteoarthritis (OA) is the most common joint disease
worldwide, and primarily affects the knees, hips, hands,
and spine. It is a leading cause of disability among older
individuals and also affects their quality of life [1]. It is
characterized by the progressive degeneration of articular
cartilage, and by subchondral sclerosis resulting in pain
and joint stiffness [2].* Correspondence: wu_yanqiao@163.com; 283546806@qq.com
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unless otherwise stated.The etiology of OA is multifactorial, including genetic
and environmental risk factors. Associated genes include
GDF5 [3], ASPN [4], FRZB [5], and COL2A1 [6], while
environmental factors may include obesity [7-9], history
of knee injury [10], occupational activities [11,12], sex
hormones and structural changes [13], meniscectomy
[14], gender, and age [15]. Twin-pair and family genetic
data show that more than 50% of OA can be attributed
to genetic factors [16]. A gender difference is also appar-
ent, with females having a greater prevalence of OA after
the age of 50 years [17]. Additionally, the disease is more
common among European populations [18]. The obser-
vation that the estrogen receptor (ER) is expressed in
human articular chondrocytes and bone cells suggests
that it may be involved in the etiology of OA [19].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion affects the growth of bone cells, while ERβ partici-
pates in the formation and resorption of bone [20]. ERα
is located on chromosome 6q25.1 and contains eight
exons and seven introns [21], as well as two common re-
striction fragment length polymorphisms (RFLPs): XbaI
and PvuII. The XbaI RFLP detects an A–G substitution
at position 351 (−351int A/G; rs9340799), while PvuII
detects a T–C substitution at position 397 (−397int T/C;
rs2234693). A previous meta-analysis confirmed the as-
sociation between bone mineral density and ERα [22].
A number of studies have investigated the association
between ERα polymorphisms and the risk of OA in dif-
ferent populations, but the results are inconsistent. Some
discovered that ERα polymorphisms were associated with
an increased risk of OA [23-28], while others found no
association with OA risk [28,29], or an association with
a reduced risk of OA [30-34]. To our knowledge, no
systematic review has examined the evidence for a rela-
tionship between ERα polymorphisms and OA. Therefore,
we conducted a meta-analysis to analyze the association
between ERα polymorphisms and OA susceptibility.-
-
Figure 1 Flow diagram of study selection according to the PRISMA stMethods
This systematic review was conducted according to 2009
PRISMA guidelines [35].Search strategy
We performed a systematic research of available studies
that assessed the association between ERα polymorphisms
and OA. We carried out a comprehensive literature search
for published studies in OVID MEDLINE, EMBASE,
CBM, and PubMed databases, and Google Scholar. Pri-
mary key search terms included estrogen receptor, poly-
morphism, osteoarthritis, and OA. Index terms for OVID
MEDLINE were: “estrogen receptor”, “polymorphism”,
and “osteoarthritis” or “OA”. The last query was updated
on 30 November 2014. There were no language or other
limitations on the search. Reference lists in the retrieved
articles or relevant reviews were also screened to iden-
tify other eligible studies. We also searched unpublished
studies by contacting clinical experts and the Arthritis
Foundation National Office. A flow diagram of our lit-
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Eligible studies were required to satisfy the following cri-
teria: (1) the study was a cohort or a case–control study;
(2) OA was diagnosed based on clinical criteria defined by
the American College of Rheumatology; (3) the original
study assessed the association between ERα polymor-
phisms (XbaI or PvuII) and OA susceptibility; and (4) the
study provided sufficient genetic frequency or sufficient
data for extraction. If overlapping study populations were
identified between studies, only the most complete one
was included in the meta-analysis. Animal studies and
literature reviews were excluded.
Quality assessment of included studies
Study quality was independently assessed by two au-
thors, based on the Newcastle–Ottawa scale (NOS)
quality score systems [36]. The NOS contains eight
items divided into three categories: selection, compar-
ability, and outcome (for cohort studies) or exposure
(for case–control studies). Quality scores ranged from 0
to 9. When there was disagreement on the quality scores
between the two authors, discrepancies were resolved
through discussion and consultation with a third author.
The quality of included studies was also assessed by
the Hardy–Weinberg equilibrium (HWE) for the control
genotype distribution. Studies consistent with HWE
were defined as high-quality, while those inconsistent
with HWE were defined as low-quality studies.
Data extraction
The following data were extracted from each full-text
study using a standardized data extraction form: the
name of the first author, year of publication, country in
which the study was performed, study design, number of
cases and controls, gender, age, genotyping, OA site, OA
definition, polymorphism, and numbers of cases and
controls for each of the PvuII (rs2234693), and XbaI
(rs9340799) genotypes. When the information extracted
from studies was inconsistent, disagreement was re-
solved through discussion and consultation with a third
author until consensus was achieved on every item.
Statistical analysis
STATA 12.0 and Review Manager 5.2 software were
used for data analysis. The pooled odds ratio (OR) and
its 95% confidence interval (95% CI) were calculated to
assess the association between ERα polymorphisms and
the risk of OA for the following contrasts: G vs. A, AG
vs. AA + GG, GG vs. AG + AA, AA vs. AG + GG, C vs.
T, CC vs. TT + CT, CT vs. CC + TT, and TT vs. CC +
CT. Subgroup analysis based on ethnicity was also per-
formed. The Chi-square test was used to determine if
the identified study was consistent with HWE for the
control genotype distribution. Heterogeneity betweenstudies was evaluated with the I2 test and the Q statistic.
We used the Cochrane system for heterogeneity grading:
I2 0–40%, might not be important; 30–60%, moderate het-
erogeneity; 50–90%, substantial heterogeneity; 75–100%,
considerable heterogeneity. Heterogeneity was assessed to
be significant when I2 > 30% or when P < 0.1 for Q
statistics.
The pooled effects were estimated using the Der-
Simonian and Laird method for random effects and the
Mantel–Haenszel method for fixed effects [37]. If the
studies were significantly heterogeneous, we used the
random effects model. Otherwise, we used the fixed ef-
fects model to calculate the pooled OR and 95%CI. The
random effects model assumes that different studies
have substantial diversity and assesses both within-study
sampling error and between-study variation [38]. The
fixed effects model assumes that genetic factors have
similar effects on OA susceptibility across all studies,
and that observed variations between studies are caused
by chance alone [39]. Sensitivity analyses were performed
for the effect size omitting the trial for which data were
imputed, and were used to evaluate the stability of the
results. Publication bias was graphically represented by
funnel plots and further evaluated with the Begg’s test
and Egger’s test [40,41].
Results
Search results and studies included in the meta-analysis
Seventy-seven relevant studies were preliminarily identi-
fied in the database search, of which 11 [24-34] eventually
satisfied the eligibility criteria for our meta-analysis. All in-
cluded studies investigated the relationship between ERα
polymorphisms and OA susceptibility. Of these, one study
[33] contained data on three different OA sites and four
different geographical locations, so these seven compar-
isons were treated independently. Therefore, a total of
17 separate comparisons were included in the present
meta-analysis. Ten studies with a total of 8,502 partici-
pants (2,181 OA patients and 6,321 controls), which in-
volved three European and seven Asian populations,
evaluated the association between the ERα XbaI poly-
morphism and OA susceptibility, while 17 with 16,159
total participants (5,325 OA patients and 10,834 controls),
involving 10 European and seven Asian populations,
evaluated the association between the ERα PvuII poly-
morphism and OA susceptibility. Study characteristics
are summarized in Table 1.
Allele and genotype counts
Allelic counts of the ERα XbaI polymorphism were eval-
uated for G and A alleles. In general, the frequency of
the A allele was higher in OA cases than in controls.
Genotype counts of the ERα XbaI polymorphism were
evaluated for GG, AG, and AA genotypes, and the
Table 1 Characteristics of the included studies
Study [Ref.] Year Country (City) Study
design
Genotyping Numbers Gender (M/F) Age Polymorphism (s) Quality
score
OA Control OA Control OA Control
Toshio Ushiyama et al. [24] 1998 Japan Case–control PCR 65 318 0/65 0/318 68.5 (49–86) 49-86 XbaI, PvuII 7 (2/2/3)
John Loughlin et al. [29] 2000 UK (Oxford) Case–control PCR 371 369 155/216 221/148 73 (56–90) 73 (59–89) XbaI, PvuII 8 (3/2/3)
Barton L. Wise et al. [30] 2009 USA Cohort PCR 307 214 258/263 61 ± 9 XbaI 8 (4/2/2)
Barton L. Wise et al. [30] 2009 USA Cohort PCR 304 211 253/262 61 ± 9 PvuII
V. M. Borgonio-Cuadra et al. [32] 2012 Mexico Case–control PCR 115 117 23/92 20/97 57.4 ± 9.2 51.8 ± 8.9 XbaI, PvuII 9 (4/2/3)
J. A. Riancho et al. [33] 2010 Spain (Santander) Case–control PCR 272 802 95/177 285/517 72 ± 7 71 ± 10 PvuII 8 (3/2/3)
J. A. Riancho et al. [33] 2010 Spain (Santiago) Case–control PCR 254 473 47/207 295/178 68 ± 6 68 ± 9 PvuII
J. A. Riancho et al. [33] 2010 UK (Oxford) Case–control PCR 445 862 176/269 471/391 64 ± 5 69 ± 7 PvuII
J. A. Riancho et al. [33] 2010 Spain (Santander) Case–control PCR 359 802 180/179 285/517 71 ± 7 71 ± 10 PvuII
J. A. Riancho et al. [33] 2010 Spain (Coruña) Case–control PCR 252 244 90/162 97/147 67 ± 14 65 ± 13 PvuII
J. A. Riancho et al. [33] 2010 Spain (Santiago) Case–control PCR 287 473 110/177 295/178 68 ± 5 68 ± 9 PvuII
J. A. Riancho et al. [33] 2010 UK (Oxford) Case–control PCR 1278 862 503/775 471/391 65 ± 6 69 ± 7 PvuII
K. Lian M.D. et al. [31] 2007 USA Cohort PCR 569 4134 0/569 0/4134 79.6 ± 5.0 78.4 ± 4.6 XbaI, PvuII 8 (4/2/2)
Sheng-Yu Jin et al. [25] 2004 Korea Case–control PCR 151 397 53/98 190/207 58.8 ± 9.6 / XbaI, PvuII 8 (3/2/3)
Zhi Tian et al. [28] 2009 China Case–control PCR 38 40 0/38 0/40 59.2 ± 3.2 58.5 ± 8.6 XbaI, PvuII 7 (2/2/3)
Jiexiang Yang et al. [34] 2009 China Case–control PCR 41 40 31/50 54.6 (28–82) XbaI, PvuII 6 (2/1/3)
Yan Xue et al. [27] 2004 China Case–control PCR 55 176 0/55 0/176 58.7 ± 2.4 60 ± 10 XbaI, PvuII 7 (3/1/3)













Table 2 Genotype and allele counts for the ERα XbaI polymorphism in the included studies
Group Study Country OA site X (G) x (A) xx (AA) Xx (AG) XX (GG)
OA Control OA Control OA Control OA Control OA Control
European Barton L. Wise et al. USA Hand 202 159 412 269 148 85 116 99 43 30
John Loughlin et al. UK Hip,Knee 256 251 486 487 164 161 158 165 49 43
K. Lian M.D. et al. USA Hip 374 2914 764 5332 257 1700 250 1932 62 491
European Total 832 3324 1662 6088 569 1946 524 2196 154 564
Asian Sheng-Yu Jin et al. Korea Knee 57 156 245 638 98 256 49 126 4 15
Toshio Ushiyama et al. Japan Hand 30 116 100 520 36 211 28 98 1 9
V. M. Borgonio-Cuadra et al. Mexico Knee 49 63 181 171 70 62 41 47 4 8
Zhi Tian et al. China Knee 24 47 52 33 18 6 16 21 4 13
Jiexiang Yang et al. China Knee 15 19 67 61 28 24 11 13 2 3
Yan Xue et al. China Knee 44 200 66 162 21 40 24 82 10 54
Xiaoyu Dai et al. China Knee 210 193 728 851 288 348 152 155 29 19
Asian Total 429 794 1439 2436 559 947 321 542 54 121
Total 1261 4118 3101 8524 1128 2893 845 2738 208 685
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than in the control group in all but one study [24]. The
frequency of the AG genotype was lower in OA cases
than in the control group in all but the same study [24].
There was no obvious difference in the frequency of theTable 3 Genotype and allele counts for the ERα PvuII polymo
Group Study Coutry (City) OA site P (C)
OA C
European Barton L. Wise et al. USA Hand 261
J. A. Riancho et al. Spain (Coruña) Hip 213
J. A. Riancho et al. UK (Oxford) Hip 1109
J. A. Riancho et al. UK (Oxford) Knee 399
J. A. Riancho et al. Spain (Santander) Hip 334
J. A. Riancho et al. Spain (Santander) Knee 246
J. A. Riancho et al. Spain (Santiago) Knee 235
J. A. Riancho et al. Spain (Santiago) Hip 239
John Loughlin et al. UK Hip,Knee 331




Asian Sheng-Yu Jin et al. Korea Knee 112




Zhi Tian et al. China Knee 29
Jiexiang Yang et al. China Knee 37
Yan Xue et al. China Knee 53
Xiaoyu Dai et al. China Knee 387
Asian Total 752
Total 4600GG genotype between OA cases and controls. Allele and
genotype counts for the ERα XbaI polymorphism in
cases and controls are shown in Table 2.
Allelic counts of the ERα PvuII polymorphism were eval-
uated for C and T alleles. In general the T allele frequencyrphism in the included studies
p (T) pp (TT) Pp (CT) PP (CC)
ontrol OA Control OA Control OA Control OA Control
192 347 230 101 65 145 100 58 46
217 291 271 89 76 113 119 50 49
776 1447 948 426 253 595 442 257 167
776 491 948 123 253 245 442 77 167
752 384 852 105 229 174 394 80 179
752 298 852 79 229 140 394 53 179
377 273 569 65 176 143 217 46 80
377 335 569 99 176 137 217 51 80
331 411 407 114 110 183 187 74 72
3835 653 4391 188 1162 277 2067 102 884
8385 4930 10037 1389 2729 2152 4579 848 1903
307 190 487 61 152 68 183 22 62
260 73 376 19 115 35 146 11 57
82 153 152 52 51 49 50 14 16
34 47 46 16 15 15 16 7 9
33 45 47 14 12 17 23 10 5
151 57 201 17 57 23 87 15 32
390 551 638 167 198 217 242 85 74
1257 1116 1947 346 600 424 747 164 255
9642 6046 11984 1735 3329 2576 5326 1012 2158
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type counts of the ERα PvuII polymorphisms were evalu-
ated for TT, CT, and CC genotypes, and the TT genotype
frequency was generally higher in OA cases than in con-
trols. The CC genotype frequency was generally lower in
OA cases than controls, although there was no obvious
difference in the frequency of the CT genotype between
the two groups. Allele and genotype counts for the ERα
PvuII polymorphism in cases and controls are shown in
Table 3.
Quality assessment of included studies
All 11 studies had a satisfactory NOS quality score as
shown in Table 1. The distribution of genotypes in the
controls was in accordance with HWE (P > 0.05) in all
studies, so all were classed as high-quality.
Meta-analysis findings
A summary of the meta-analysis findings are shown in







Test of association T
OR 95% CI p-value M
XbaI (G vs. A) Overall 10 0.87 0.73—1.04 0.13 R
European 3 0.91 0.82—1.01 0.08 F
Asian 7 0.80 0.57—1.13 0.21 R
AA vs. AG + GG Overall 10 1.16 0.94—1.44 0.17 R
European 3 1.17 1.02—1.34 0.03 F
Asian 7 1.22 0.84—1.79 0.30 R
AG vs. AA + GG Overall 10 0.93 0.84—1.04 0.22 F
European 3 0.86 0.75—0.99 0.04 F
Asian 7 1.06 0.89—1.26 0.52 F
GG vs. AG + AA Overall 10 0.88 0.67—1.17 0.38 R
European 3 0.97 0.79—1.20 0.81 F
Asian 7 0.65 0.36—1.19 0.17 R
PvuII (C vs. T) Overall 17 0.98 0.93—1.03 0.37 F
European 10 0.97 0.90—1.04 0.14 R
Asian 7 1.07 0.95—1.21 0.25 F
CC vs. TT + CT Overall 17 0.97 0.89—1.06 0.55 F
European 10 0.94 0.85—1.04 0.21 F
Asian 7 1.17 0.94—1.47 0.16 F
CT vs. CC + TT Overall 17 0.99 0.92—1.06 0.75 F
European 10 1.01 0.91—1.13 0.82 R
Asian 7 0.96 0.81—1.14 0.64 F
TT vs. CC + CT Overall 17 1.01 0.92—1.12 0.79 R
European 10 1.02 0.90—1.17 0.74 R
Asian 7 0.95 0.80—1.13 0.57 Fbe associated with OA risk in all populations (G vs. A:
OR = 0.87, 95% CI = 0.73–1.04, P = 0.13; AA vs. AG +GG:
OR = 1.16, 95% CI =0.94–1.44, P = 0.17; AG vs. AA +GG:
OR = 0.93, 95% CI =0.84–1.04, P = 0.22; GG vs. AG +AA:
OR = 0.88, 95% CI =0.67–1.17, P = 0.38). However, sub-
group analysis by ethnicity showed that the AA and AG ge-
notypes of the ERα XbaI polymorphism were associated with
OA risk among Europeans (AA vs. AG+GG: OR= 1.17,
95% CI = 1.02–1.34, P= 0.03; AG vs. AA+GG: OR= 0.86,
95% CI = 0.75–0.99, P= 0.04), but not among Asian popula-
tions (Figure 2).
There was no significant association between the ERα
PvuII polymorphism and susceptibility to OA in all popu-
lations (C vs. T, OR = 0.98, 95% CI = 0.93–1.03, P = 0.37;
CC vs. TT + CT, OR = 0.97, 95% CI = 0.89–1.06, P = 0.55;
CT vs. CC +TT, OR = 0.99, 95% CI = 0.92–1.06, P = 0.75;
TT vs. CC + CT, OR = 1.01, 95% CI = 0.92–1.12, P = 0.79).
In the subgroup analysis based on ethnicity, no significant
association was found for the ERα PvuII polymorphism in
either European or Asian populations (Figure 3).nd OA susceptibility
est of heterogeneity Test of publication bias
Begg's test Egger's test
odel Q test p-value I2 Z test p-value T test p-value
andom 29.71 0.0005 70% −0.80 0.42 −1.29 0.23
ixed 1.67 0.43 0%
andom 27.74 0.0001 78%
andom 25.55 0.002 65% 1.16 0.25 0.94 0.38
ixed 1.91 0.39 0%
andom 21.69 0.001 72%
ixed 10.61 0.30 15% 0.09 0.93 0.47 0.65
ixed 1.52 0.47 0%
ixed 5.87 0.44 0%
andom 14.23 0.11 37% −0.80 0.42 1.89 0.10
ixed 0.85 0.65 0%
andom 12.58 0.05 52%
ixed 19.58 0.24 18% 0.66 0.51 0.87 0.40
andom 13.61 0.14 34%
ixed 3.19 0.78 0%
ixed 13.09 0.67 0% 0.08 0.93 0.26 0.80
ixed 5.05 0.83 0%
ixed 4.94 0.55 0%
ixed 19.85 0.23 19% 0.41 0.68 0.73 0.48
andom 15.43 0.08 42%
ixed 4.29 0.64 0%
andom 23.83 0.09 33% −0.25 0.81 −1.15 0.27
andom 20.33 0.02 56%
ixed 2.35 0.88 0%
Figure 2 Meta-analysis of the association between the ERα XbaI polymorphism and OA (AG vs. AA + GG).
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As shown in Table 4, heterogeneity was observed among
studies in all populations and also in subgroup analyses.
To explore the sources of heterogeneity across studies
we performed a sensitivity analysis, which revealed that
none of the studies significantly affected the pooled ORs
and CIs. Sequential removal of each study had little ef-
fect on the pooled ORs.
The funnel plot revealed no obvious publication bias
(Figure 4), and this was confirmed by Begg’s test and
Egger’s test.
Discussion
Although the pathogenesis of OA is considered to be the
result of many factors, genetics are thought to be one of
the most important determinants [42]. Despite the fact
that ERα is one of the most studied genes in OA [43], to
the best of our knowledge this is the first meta-analysis
of the relationship between ERα polymorphisms XbaI
and PvuII and OA risk.
Our meta-analysis included 11 published studies (with
17 comparisons) of 16,159 participants (5,325 OA pa-
tients and 10,834 controls). Ten studies with a total of
8,502 participants evaluated the association between the
ERα XbaI polymorphism and OA susceptibility, and ourmeta-analysis suggested that it was significantly associ-
ated with OA in European but not Asian populations.
The pooled OR for homozygote AA carriers showed that
they were associated with a 17% increased risk for OA
compared with AG and GG carriers, and that European
AG carriers had a decreased OA risk. The heterogeneity
of genetic effects between European and Asian popula-
tions suggests the existence of gene–environment or
gene–gene interactions. No heterogeneity was detected
in European populations with respect to the ERα XbaI
polymorphism and OA, suggesting that the genetic ef-
fect of this polymorphism is stronger in European than
Asian populations.
Seventeen studies with a total of 16,159 participants
evaluated the association between the ERα PvuII poly-
morphism and OA susceptibility. Our meta-analysis
suggested that there was no association between the
polymorphism and susceptibility to OA in any popula-
tion. The same result was obtained for the subgroup
analysis based on ethnicity.
Gender differences are known to affect the development
of OA; for example, the prevalence of knee OA is greater
in women than men [15]. Only two of the studies included
in our meta-analysis were stratified according to partici-
pant gender [25,32], and both reported no significant
Figure 4 Funnel plot of the meta-analysis of the ERα PvuII polymorphism with susceptibility to OA (C vs. T).
Figure 3 Meta-analysis of the association between the ERα PvuII polymorphism and OA (CC vs. TT + CT).
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tients and controls of the same sex. However, because of
the small number of this type of study and the limited raw
data based on gender differences in genotype distributions
and allele frequencies, we were unable to perform a sub-
group analysis according to gender.
Several limitations should be taken into consideration
in the current meta-analysis. First, it was based on un-
adjusted OR estimates because not all studies presented
adjusted ORs, or the ORs were not adjusted by the same
potential confounders, such as age and gender. This
lack of information could have caused serious con-
founding bias. Second, OA is influenced by both genetic
and environmental risk factors such as obesity, injury,
occupational activities, and meniscectomy. However,
the studies included in the meta-analysis did not control
for these environmental risk factors. Third, some studies
included individuals with OA in different sites, but we
were unable to perform subgroup analysis of this within
the same ethnic population because of the limited avail-
able data. For instance, hand OA is known to be more in-
fluenced by genetic and hormonal influences than other
types of OA, but the relationship between the ERα XbaI
polymorphism and hand OA was only reviewed in one
study of Europeans [30] and one of Asians [24]. Other
studies of the ERα XbaI polymorphism and OA suscep-
tibility in Europeans focused on three different OA
sites. Finally, although our current findings suggest that
the ERα XbaI polymorphism is associated with OA in
Europeans, it was not possible to determine whether
this polymorphism is in linkage disequilibrium with any
other potentially functional polymorphisms. However,
our meta-analysis also had some advantages, including
a satisfactory quality of all 11 included studies, and a
well-designed method.
Conclusions
The present results suggest that there may be a weak re-
lationship between the ERα XbaI polymorphism and OA
in European but not Asian populations, while the ERα
PvuII polymorphism did not appear to be associated
with OA in either Europeans or Asians. Because the
studies included in the meta-analysis reviewed the rela-
tionship between the ERα XbaI polymorphism and OA
susceptibility at three different sites in Europeans, large
well-designed studies are necessary to confirm our find-
ings in more homogeneous populations.
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